About Us

About ADVANCES

Although the management of lung cancer has improved over time with increasing survival rates, medical oncologists are regularly faced with the challenge of incorporating new immunotherapeutic and targeted treatment options in the management of patients with advanced NSCLC. Medical oncologists should be aware of the latest clinical data with cemiplimab identified in the multicenter, open-label EMPOWER-Lung 1 phase 3 study, which evaluated first-line therapy with cemiplimab in the advanced NSCLC setting among patients, regardless of PD-L1 expression. Significant improvements in terms of both progression-free survival and overall survival were observed. As prior studies, such as KEYNOTE-042 and CheckMate-227, did not conclusively show a survival benefit in patients with PD-L1 expression <50%, these results for the first time show an unequivocal treatment benefit across all patients with NSCLC, regardless of PD-L1 expression.

Differentiating the newest therapies from earlier treatments, such as pembrolizumab, nivolumab, durvalumab, and atezolizumab, remains an important challenge in medical oncologists. It is important for clinicians to offer the most up-to-date treatment regimens to their patients with newly diagnosed advanced NSCLC. By integrating these data, oncologists are able to reduce uncertainty and improve their confidence in the use of therapeutic strategies that have unequivocal benefit, regardless of initial tumor proportion scores.

About Med Learning Group

Med Learning Group, is a full-service, accredited medical education company. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for both the patient and the practitioner.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive, and patient-centric in nature. We apply adult learning theory and principles to our programs and, more importantly, understand the nuances of our specialty audiences. We design programs for physicians, nurses, pharmacists, and other healthcare practitioners and have a deep understanding of how to educate both specialty audiences and general practitioners. The mission of Med Learning Group is to design educational activities for healthcare practitioners that increase competence, change behavior, and optimize patient care. The major focus of our education is the creation of innovative and interactive educational programs designed with scientific rigor, fair balance, and evidence-based content.

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Ophthalmologist-in-Chief
Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX

Search

[divi_global_search_form]

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for retinopathy of prematurity (ROP). Click on one of the options below to learn more about ROP.

Patient Toolkit

Patient Toolkit

Read more

What exactly is NSCLC?

What exactly is NSCLC?

Read more

What symptoms can NSCLC cause?

What symptoms can NSCLC cause?

Read more

How is NSCLC treated according to staging?

How is NSCLC treated according to staging?

Read more

How is early NSCLC treated with surgery or SBRT?

How is early NSCLC treated with surgery or SBRT?

Read more

When is chemotherapy used in NSCLC?

When is chemotherapy used in NSCLC?

Read more

When is radiation used in NSCLC?

When is radiation used in NSCLC?

Read more

When is immunotherapy used in NSCLC?

When is immunotherapy used in NSCLC?

Read more

When is targeted therapy used in NSCLC?

When is targeted therapy used in NSCLC?

Read more

Online resources

Online resources

Read more
This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | ROP Relief | All Rights Reserved | Website by Divigner